Compare Biocon Ltd with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ALEMBIC LTD - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ALEMBIC LTD BIOCON /
ALEMBIC LTD
 
P/E (TTM) x 25.6 73.8 34.7% View Chart
P/BV x 3.4 2.6 129.2% View Chart
Dividend Yield % 0.3 0.4 87.8%  

Financials

 BIOCON    ALEMBIC LTD
EQUITY SHARE DATA
    BIOCON
Mar-18
ALEMBIC LTD
Mar-18
BIOCON /
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,18872 1,650.0%   
Low Rs30534 899.7%   
Sales per share (Unadj.) Rs68.74.7 1,462.0%  
Earnings per share (Unadj.) Rs7.66.1 123.7%  
Cash flow per share (Unadj.) Rs14.06.2 223.7%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.10.4 35.5%  
Book value per share (Unadj.) Rs86.340.7 212.4%  
Shares outstanding (eoy) m600.00267.03 224.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.911.3 96.4%   
Avg P/E ratio x98.98.7 1,139.5%  
P/CF ratio (eoy) x53.48.5 630.2%  
Price / Book Value ratio x8.61.3 663.9%  
Dividend payout %13.23.3 404.1%   
Avg Mkt Cap Rs m447,90014,139 3,167.8%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,311207 4,489.4%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,2341,255 3,285.1%  
Other income Rs m2,062370 557.0%   
Total revenues Rs m43,2961,625 2,663.7%   
Gross profit Rs m8,291111 7,462.6%  
Depreciation Rs m3,85138 10,187.8%   
Interest Rs m6152 36,176.5%   
Profit before tax Rs m5,887442 1,332.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56924 6,551.1%   
Profit after tax Rs m4,5311,630 278.0%  
Gross profit margin %20.18.9 227.2%  
Effective tax rate %26.75.4 491.6%   
Net profit margin %11.0129.8 8.5%  
BALANCE SHEET DATA
Current assets Rs m41,4861,867 2,221.9%   
Current liabilities Rs m21,413591 3,622.0%   
Net working cap to sales %48.7101.6 47.9%  
Current ratio x1.93.2 61.3%  
Inventory Days Days6494 67.9%  
Debtors Days Days9474 128.1%  
Net fixed assets Rs m50,6611,791 2,828.8%   
Share capital Rs m3,000534 561.7%   
"Free" reserves Rs m48,80810,324 472.8%   
Net worth Rs m51,80810,858 477.2%   
Long term debt Rs m17,89841 43,441.7%   
Total assets Rs m99,89711,591 861.9%  
Interest coverage x10.6260.9 4.1%   
Debt to equity ratio x0.30 9,104.3%  
Sales to assets ratio x0.40.1 381.1%   
Return on assets %5.214.1 36.6%  
Return on equity %8.715.0 58.3%  
Return on capital %9.615.2 63.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m12,05819 62,154.6%   
Fx outflow Rs m7,348264 2,785.2%   
Net fx Rs m4,710-244 -1,927.0%   
CASH FLOW
From Operations Rs m6,621236 2,807.9%  
From Investments Rs m-6,840-224 3,053.6%  
From Financial Activity Rs m-2,397-27 9,011.3%  
Net Cashflow Rs m-2,612-15 17,648.6%  

Share Holding

Indian Promoters % 40.4 64.0 63.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,200.0%  
FIIs % 10.7 9.7 110.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.1 76.2%  
Shareholders   109,995 54,701 201.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   IPCA LABS  SANOFI INDIA  ALKEM LABORATORIES  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Dec 13, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS